- Report
- October 2022
- 70 Pages
Africa
From €4351EUR$4,750USD£3,698GBP
- Report
- August 2023
- 150 Pages
North America
From €4351EUR$4,750USD£3,698GBP
- Report
- February 2022
- 62 Pages
Global
From €3206EUR$3,500USD£2,725GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- May 2025
- 50 Pages
Global
From €2428EUR$2,650USD£2,063GBP
Exenatide is a drug used to treat endocrine and metabolic disorders. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to regulate glucose levels in the body. Exenatide is used to treat type 2 diabetes, and is administered as a subcutaneous injection. It works by stimulating the release of insulin from the pancreas, and by slowing the rate of glucose absorption from the gastrointestinal tract.
Exenatide is available in two forms: a long-acting version (Bydureon) and a short-acting version (Byetta). Both versions are used to improve glycemic control in adults with type 2 diabetes, and can be used in combination with other diabetes medications. Exenatide has been shown to reduce the risk of cardiovascular events in patients with type 2 diabetes.
Exenatide is marketed by several companies, including AstraZeneca, Eli Lilly, and Novo Nordisk. It is also available as a generic drug in some countries. Show Less Read more
